Insulin delivery and diabetes technology firm Tandem Diabetes Care said that its t:slim X2 insulin pump is now approved for use with Eli Lilly’s Lyumjev (insulin lispro-aabc injection) in the European Union (EU).
The t:slim X2 insulin pump with Control-IQ automated insulin delivery (AID) technology will be used with ultra-rapid acting insulin to enhance treatment options for diabetes patients.
The pump is currently approved for use with Humalog and Novolog/NovoRapid U-100 insulins worldwide.
In Canada and select EU countries, it is also cleared for use with Admelog/Insulin lispro Sanofi and Trurapi/Insulin aspart Sanofi U-100 insulins.
Lyumjev was authorised for general use in insulin pumps in the EU in 2020.
In 2021, the US Food and Drug Administration (FDA) approved the label expansion of Lyumjev to include administration through continuous subcutaneous insulin infusion (CSII) with an insulin pump.
However, pump manufacturers must conduct testing to ensure compatibility with individual pumps and AID systems.
California-based Tandem Diabetes Care and Lilly collaborated on a clinical trial that demonstrated the benefits of using Lyumjev with Control-IQ technology.
Both partners are now working to secure Lyumjev compatibility for the t:slim X2 pump in additional regions and for the Tandem Mobi pump.
Tandem Diabetes Care chief medical officer Jordan Pinsker said: “High satisfaction and quality of life benefits were recently shown in a clinical study using Lyumjev with Control-IQ technology.
“Ultra-rapid acting insulin is a popular choice for people living with diabetes due to its fast response time.
“We are proud to be able to offer Lyumjev compatibility with our t:slim X2 pump as part of an AID system in the EU, providing more flexibility for our customers in these countries.”
Tandem Diabetes Care manufactures advanced automated insulin delivery systems to simplify diabetes management.
Its portfolio includes the Tandem Mobi system and the t:slim X2 insulin pump.
In May, the diabetes technology firm announced that its Tandem Mobi insulin pump is now fully compatible with both the Dexcom G7 and Dexcom G6 Continuous Glucose Monitoring (CGM) Systems.
